Immucell Corp (ICCC) — Analysis Summary
Immucell Corp (ICCC) has a market cap of $87.19M with year-over-year revenue growth of +4.3%. Net margin stands at -3.8%. The stock trades at a P/E ratio of 110.7.
Key Takeaways
- Revenue changed +4.3% year-over-year
- Net margin of -3.8%
- P/E ratio of 110.7
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, ICCC posted revenue growth of +4.3% and trades at a P/E of 110.7.
Immucell Corp (ICCC)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees
73
Headquarters
PORTLAND, ME
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.